

References

Peripheral neuropathy

1,2

Stem cell transplant

3-5

1. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. *Lancet Oncol.* 2011;12(5):431-440.
2. Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. *Blood.* 2010;115(16):3416-3417.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. *New England Journal of Medicine.* 1996;335(2):91-97.
4. Attal M, Harousseau J, Facon T, IFM ft. Single versus Double Transplant in Myeloma: A Randomized Trial of the Inter Group Francais du Myelome. Proceedings of the VIII International Myeloma Workshop. Banff, Alberta, Canada; 2001.
5. Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. *Blood.* 2011;118(3):529-534.